Valerie G. Brunton

This study shows that Kindlin-1 loss in cutaneous squamous cell carcinoma disrupts ECM-vascular organization, leading to hypoxia and tumor progression.

This study screens a large compound library across patient-derived GBM stem cells to identify effective drugs targeting tumor heterogeneity and presents validated hits for further exploration.

This paper shows that FAK inhibition remodels the metastatic ECM, enhancing CD8+ T cell infiltration and immunosurveillance in breast cancer.

This study shows that systemic FAK inhibition reduces immunosuppressive macrophages in glioblastoma by blocking monocyte trafficking, enhancing T cell activity and improving survival in a mouse model.

This study shows FAK regulates glycolysis and glutamine oxidation in glioblastoma stem cells, affecting mitochondrial morphology and cell migration.

This study shows that inhibiting USP18 enhances type I interferon signaling and immune activation in TNBC, converting immunologically cold tumors into hot ones and improving immunotherapy efficacy.

This study identifies a synergistic combination of FAK and MEK inhibitors that effectively targets glioblastoma heterogeneity and improves therapeutic outcomes.